New Delhi: In a regulatory filing, Glenmark Pharmaceuticals, on Monday, announced price reduction by 27 per cent to Rs 75 per tablet, for its antiviral drug Favipiravir, under the brand name FabiFlu.
Earlier, the cost of FabiFlu was Rs 103 per tablet. It is used for the treatment of the patients with mild to moderate COVID-19 infection.
“The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark’s facilities in India, the benefits of which are being passed on to patients in the country,” the filing said, as quoted by The Indian Express.
Further, the company has commenced a post marketing surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1,000 patients that are prescribed with the oral antiviral, as part of an open label, multi-center, single arm study, the filing added.
“And now we hope that this further price reduction will make it even more accessible for patients across the country. We expect this post marketing surveillance study to shed more light on the drug’s clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu,” Glenmark Pharmaceuticals Senior vice-president and Head India business Alok Malik was quoted as saying.
Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India. The trial results will be available shortly, the company said.
